Trevi Therapeutics, Inc. TRVI
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
17.77
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$42.8M | — | -$42.1M | $183.2M |
| 2024 | — | -$47.9M | — | -$38.3M | $99.6M |
| 2023 | — | -$29.1M | — | -$31.8M | $82.5M |
| 2022 | — | -$29.2M | — | -$28.3M | $107.5M |
| 2021 | — | -$33.9M | — | — | $17.1M |
| 2020 | — | -$32.8M | — | -$29.0M | $27.3M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 17.77 (safe)
- Working capital / assets 0.94
- Retained earnings / assets -1.705
- EBIT / assets -0.255
- Equity / liabilities 17.974
Source: SEC EDGAR filings · CIK 0001563880 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.